Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Non-DEHP and Phthalate-Free Tubing Now Available for Routine Laboratory Applications

By BiotechDaily International staff writers
Posted on 27 Aug 2013
A major European manufacturer of high-performance flexible tubing and other plastic laboratory products has introduced a bio-based, phthalate-free product for use in routine laboratory applications.

Saint-Gobain Performance Plastics (Paris, France) the manufacturer of Tygon high-performance flexible tubing, has recently introduced a bio-based, phthalate-free product. DEHP Di(2-ethylhexyl phthalate), a common plasticizer, has been removed from existing Tygon formulations.

The next-generation DEHP- and phthalate-free Tygon S3 tubing is made with a bio-based plasticizer and the product’s new sustainable formulations are biodegradable and deliver superior pump life. For example, Tygon S3 E-3603 non-DEHP tubing was specially formulated for resistance to flex-fatigue and abrasion. In many peristaltic pump applications, it outlasts the original R-3603 by a factor of three to one. As tubing for an instrumentation connection, vent, drain and other general laboratory applications, Tygon S3 E-3603 Tubing offers superior life, which minimizes the labor and expense of replacement.

New Tygon S3 formulations include Tygon S3 E-3603 General Laboratory Tubing and Tygon S3 E-LFL Long Flexible Life Tubing. Tygon R-1000 has also been replaced by Tygon E-1000, soft and flexible non-DEHP tubing.

“The change to non-DEHP tubing is integral to the company’s continued efforts toward safety, compliance, and sustainability,” said Katia May, laboratory market manager for Saint-Gobain Performance Plastics. “Saint-Gobain is the first manufacturer to remove DEHP and phthalates from tubing products for laboratory applications and beyond. We are committed to providing superior, smart, safe, and sustainable flexible tubing with unsurpassed performance.”

Related Links:




view channel
Image: Schematic representation of HIV DART binding to two distinct antigens simultaneously, redirecting the killer T-cells to destroy HIV-1 infected cells (Photo courtesy of Duke University).

Bi-Specific Antibodies Shown to Clear Latent HIV Infections

Bi-specific antibodies or DARTS (dual-affinity re-targeting proteins) have been used to eliminate latent HIV-infection from patient samples by redirecting polyclonal T-cells to specifically engage with... Read more

Drug Discovery

view channel
Image: Use of catchphrase terms like “breakthrough” and “promising” in public news media presenting new drugs tends to result in incorrect assumptions and conclusions about the meaning and significance of criteria for FDA breakthrough-designated and accelerated-approval drugs (Photo courtesy of Dartmouth Institute).

Words That Inappropriately Enhance Perception of New Drug’s Effectiveness

Researchers have found that using the words “breakthrough” and “promising” in presenting a new drug to the general public often has a dramatic effect on judgment about its effectiveness.... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.